Biodesix (BDSX) OCF Yield: History & Chart

Biodesix, Inc.(BDSX)

Medical - Diagnostics & Research · Louisville, CO

$29.55+0.49 (+1.69%)

Delayed quote: Oct 6, 2026, 9:34 AM EDT

About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Louisville, CO

334 employees

www.biodesix.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Scott Hutton

View full financials

NAME	MARKET CAP	OPERATING CASH FLOW YIELD	TTM	3Y	5Y
Biodesix, Inc. (BDSX)	$240.55M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$240.76M	7.43%	8.86%	9.94%	8.17%
Akebia Therapeutics, Inc. (AKBA)vs ›	$239.39M	17.36%	15.21%	15.21%	15.21%
BioAge Labs Inc. (BIOA)vs ›	$241.18M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$244.19M	N/A	1.55%	1.55%	2.54%
Alector, Inc. (ALEC)vs ›	$232.03M	N/A	41.63%	41.53%	35.39%
Galectin Therapeutics Inc. (GALT)vs ›	$246.96M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$229.20M	N/A	14.77%	14.64%	14.64%
InflaRx N.V. (IFRX)vs ›	$248.92M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$249.82M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

OPERATING CASH FLOW YIELD

TTM

Biodesix, Inc. (BDSX)

$240.55M

N/A

High Tide Inc. (HITI)vs ›

$240.76M

7.43%

8.86%

9.94%

8.17%

Akebia Therapeutics, Inc. (AKBA)vs ›

$239.39M

17.36%

15.21%

BioAge Labs Inc. (BIOA)vs ›

$241.18M

N/A

Lifecore Biomedical, Inc. (LFCR)vs ›

$244.19M

N/A

1.55%

2.54%

Alector, Inc. (ALEC)vs ›

$232.03M

N/A

41.63%

41.53%

35.39%

Galectin Therapeutics Inc. (GALT)vs ›

$246.96M

N/A

Keros Therapeutics, Inc. (KROS)vs ›

$229.20M

N/A

14.77%

14.64%

InflaRx N.V. (IFRX)vs ›

$248.92M

N/A

Greenwich LifeSciences, Inc. (GLSI)vs ›

$249.82M

N/A

Operating Cash Flow Yield Formula & Definition

OCF Yield = TTM Operating Cash Flow / Market Cap

Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).

Operating Cash Flow Yield: N/A

BDSX Operating Cash Flow Yield Metrics

BDSX Competitors' Operating Cash Flow Yield

Operating Cash Flow Yield Formula & Definition

Related Metrics